Orchestra BioMed Holdings (OBIO) Income towards Parent Company (2021 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Income towards Parent Company for 6 consecutive years, with -$24.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company fell 27.72% year-over-year to -$24.8 million; the TTM figure through Mar 2026 stood at -$60.5 million (up 22.77% YoY), while the FY2025 annual figure was -$160.1 million, down 1.18% from the prior year.
• Income towards Parent Company fell to -$24.8 million in Q1 2026 per OBIO's latest filing, from $6.4 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $6.4 million in Q4 2025 and bottomed at -$25.2 million in Q2 2024.
• Historically, Income towards Parent Company has averaged -$14.8 million across 5 years, with a median of -$16.1 million in 2024.
• Annual changes were most pronounced in 2022 — Income towards Parent Company plunged 8300.5% — and 2025, when it soared 139.71%.
• Orchestra BioMed Holdings' Income towards Parent Company stood at -$10.1 million in 2022, then fell by 23.72% to -$12.5 million in 2023, then decreased by 28.98% to -$16.1 million in 2024, then surged by 139.71% to $6.4 million in 2025, then tumbled by 487.22% to -$24.8 million in 2026.
• Business Quant data shows OBIO's Income towards Parent Company at -$24.8 million in Q1 2026, $6.4 million in Q4 2025, and -$20.5 million in Q3 2025.